Hematological Parameters Improve Prediction of Mortality and Secondary Adverse Events in Coronary Angiography Patients

Medicine (United States)

Volumn 94, Issue 45, 2015, Pages e1992-

  Gijsberts, Crystel M ^a,b   Den Ruijter, Hester M ^a,b   De Kleijn, Dominique P V ^a   Huisman, Albert ^a   Ten Berg, Maarten J ^a   Van Wijk, Richard H A ^a   Asselbergs, Folkert W ^b   Voskuil, Michiel ^b   Pasterkamp, Gerard ^a   Van Solinge, Wouter W ^a   Hoefer, Imo E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

AGED; ANGIOCARDIOGRAPHY; BLOOD; BLOOD EXAMINATION; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MIDDLE AGED; MORTALITY; PROGNOSIS; RADIOGRAPHY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; HEMATOLOGIC TESTS; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84958231505     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001992     Document Type: Article

References (65)

1. Nauta ST, Deckers JW, Akkerhuis M, Lenzen M, Simoons ML, van Domburg RT. Changes in clinical profile, treatment, and mortality in patients hospitalised for acute myocardial infarction between 1985 and 2008. PLoS One. 2011;6:e26917.
2. Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health. 1951;41:279-281.
3. Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-733.
4. Garcia-Moll X, Zouridakis E, Cole D, et al. C-reactive protein in patients with chronic stable angina: differences in baseline serum concentration between women and men. Eur Heart J. 2000;21:1598-1606.
5. Shlipak MG, Sarnak MJ, Katz R, et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med. 2005;352:2049-2060.
6. Luc G, Bard J-M, Lesueur C, et al. Plasma cystatin-C and development of coronary heart disease: the PRIME Study. Atherosclerosis. 2006;185:375-380.
7. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142.
8. Wong ND, Gransar H, Narula J, et al. Myeloperoxidase, subclinical atherosclerosis, and cardiovascular disease events. JACC Cardiovasc Imaging. 2009;2:1093-1099.
9. Lee CD, Folsom AR, Nieto FJ, et al. White blood cell count and incidence of coronary heart disease and ischemic stroke and mortality from cardiovascular disease in African-American and White men and women: atherosclerosis risk in communities study. Am J Epidemiol. 2001;154:758-764.
10. Gillum RF, Mussolino ME, Madans JH. Counts of neutrophils, lymphocytes, and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol. 2005;15:266-271.
11. Lappegard J, Ellingsen TS, Vik A, et al. Red cell distribution width and carotid atherosclerosis progression. Thromb Haemost. 2015;113:649-654.
12. Sahin O, Akpek M, Sarli B, et al. Association of red blood cell distribution width levels with severity of coronary artery disease in patients with non-ST elevation myocardial infarction. Med Princ Pract. 2014;24:178-183.
13. Perlstein TS, Weuve J, Pfeffer MA, et al. Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med 2009;169:588-594.
14. Widlansky ME, Sesso HD, Rexrode KM, et al. Body mass index and total and cardiovascular mortality in men with a history of cardiovascular disease. Arch Intern Med. 2004;164:2326-2332.
15. Shimada YJ, Cannon CP. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur Heart J. 2015;36:2415-2424.
16. Gijsberts CM, Gohar A, Ellenbroek GHJM, et al. Severity of stable coronary artery disease and its biomarkers differ between men and women undergoing angiography. Atherosclerosis. 2015;241: 234-240.
17. ten Berg MJ, Huisman A, van den Bemt PM, et al. Linking laboratory and medication data: new opportunities for pharmacoepidemiological research. Clin Chem Lab Med 2007;45:13-19.
18. Gijsberts CM, Seneviratna A, de Carvalho LP, et al. Ethnicity modifies associations between cardiovascular risk factors and disease severity in parallel Dutch and Singapore coronary cohorts. PLoS One. 2015;10:e0132278.
19. Harris PJ, Behar VS, Conley MJ, et al. The prognostic significance of 50% coronary stenosis in medically treated patients with coronary artery disease. Circulation. 1980;62:240-248.
20. Lam SW, Leenen LPH, Van Solinge WW, et al. Evaluation of hematological parameters on admission for the prediction of 7-day in-hospital mortality in a large trauma cohort. Clin Chem Lab Med. 2011;49:493-499.
21. Groeneveld KM, Heeres M, Leenen LPH, et al. Immunophenotyping of posttraumatic neutrophils on a routine haematology analyser. Mediators Inflamm. 2012;2012
22. Groeneveld KM, Heeres M, Leenen LPH, Huisman A, Koenderman L. Immunophenotyping of posttraumatic neutrophils on a routine haematology analyser. Mediators Inflamm. 2012;2012:509513.
23. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. PLoS Med. 2007;4:e296.
24. Binder H. CoxBoost: Cox models by likelihood based boosting for a single survival endpoint orf competing risks. 2013; 2-14.
25. Blanche P, Dartigues J-F, Jacqmin-Gadda H. Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks. Stat Med. 2013;32:5381-5397.
26. Chiang C-T, Hung H. Non-parametric estimation for time-dependent AUC. J Stat Plan Inference. 2010;140:1162-1174.
27. Uno H, Tian L, Cai T, et al. A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med. 2013;32:2430-2442.
28. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011;30:11-21.
29. Sniderman AD, D'Agostino RB, Pencina MJ. The role of physicians in the era of predictive analytics. JAMA. 2015;314:25-26.
30. Allaire J. RStudio: Integrated development environment for R. Boston, MA 2012.
31. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria; 2014.
32. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models. Epidemiology. 2010;21: 128-138.
33. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med. 2010;48:1703-1711.
34. Salvagno GL, Sanchis-Gomar F, Picanza A, et al. Red blood cell distribution width: a simple parameter with multiple clinical applications. Crit Rev Clin Lab Sci. 2014;8363:1-20.
35. Garbharran U, Chinthapalli S, Hopper I, et al. Red cell distribution width is an independent predictor of mortality in hip fracture. Age Ageing. 2013;42:258-261.
36. Karagöz E, Tanoglu A. Red blood cell distribution width: an emerging predictor for mortality in critically ill patients? Neth J Med. 2014;72:2014;115:.
37. Kim CH, Kim SJ, Lee MJ, et al. An increase in mean platelet volume from baseline is associated with mortality in patients with severe sepsis or septic shock. PLoS One. 2015;10:e0119437.
38. Lorente L, Martn MM, Abreu-González P, et al. Red blood cell distribution width during the first week is associated with severity and mortality in septic patients. PLoS One. 2014;9:e105436.
39. Kara H, Degirmenci S, Bayir A, et al. Red cell distribution width and neurological scoring systems in acute stroke patients. Neuropsychiatr Dis Treat. 2015;11:733-739.
40. Söderholm M, Borné Y, Hedblad B, et al. Red cell distribution width in relation to incidence of stroke and carotid atherosclerosis: a population-based cohort study. PLoS One. 2015;10:e0124957.
41. Bekler A, Tenekecioglu E, Erbag G, et al. Relationship between red cell distribution width and long-term mortality in patients with non-ST elevation acute coronary syndrome. Anatol J Cardiol. 2015;15: 634-639.
42. Sun X, Chen W, Sun Z, et al. Impact of red blood cell distribution width on long-term mortality in patients with ST-elevation myocardial infarction. Cardiology. 2014;128:343-348.
43. Ephrem G. Red blood cell distribution width is a predictor of readmission in cardiac patients. Clin Cardiol. 2013;36:293-299.
44. Cavusoglu E, Chopra V, Gupta A, et al. Relation between red blood cell distribution width (RDW) and all-cause mortality at two years in an unselected population referred for coronary angiography. Int J Cardiol. 2010;141:141-146.
45. Tsuboi S, Miyauchi K, Kasai T, et al. Impact of red blood cell distribution width on long-term mortality in diabetic patients after percutaneous coronary intervention. Circ J. 2013;77:456-461.
46. Liu X, Ma C, Liu X, et al. Relationship between red blood cell distribution width and intermediate-term mortality in elderly patients after percutaneous coronary intervention. J Geriatr Cardiol. 2015;12:17-22.
47. Jung C, Fujita B, Lauten A, et al. Red blood cell distribution width as useful tool to predict long-term mortality in patients with chronic heart failure. Int J Cardiol. 2011;152:417-418.
48. Núñez J, Núñez E, Rizopoulos D, et al. Red blood cell distribution width is longitudinally associated with mortality and anemia in heart failure patients. Circ J. 2014;78:410-418.
49. Dai Y, Konishi H, Takagi A, et al. Red cell distribution width predicts short-and long-term outcomes of acute congestive heart failure more effectively than hemoglobin. Exp Ther Med 2014;8:600-606.
50. Van Kimmenade RRJ, Mohammed AA, Uthamalingam S, et al. Red blood cell distribution width and 1-year mortality in acute heart failure. Eur J Heart Fail 2010;12:129-136.
51. Pascual-Figal DA, Bonaque JC, Redondo B, et al. Red blood cell distribution width predicts long-term outcome regardless of anaemia status in acute heart failure patients. Eur J Heart Fail. 2009;11:840-846.
52. ó Hartaigh B, Bosch JA, Thomas GN, et al. Which leukocyte subsets predict cardiovascular mortality From the LUdwigshafen RIsk and Cardiovascular Health (LURIC) Study. Atherosclerosis. 2012;224:161-169.
53. Haumer M, Amighi J, Exner M, et al. Association of neutrophils and future cardiovascular events in patients with peripheral artery disease. J Vasc Surg. 2005;41:610-617.
54. Pinto EM, Huppert FA, Morgan K, et al. Neutrophil counts, monocyte counts and cardiovascular disease in the elderly. Exp Gerontol. 2004;39:615-619.
55. Buttari B, Profumo E, Riganò R. Crosstalk between red blood cells and the immune system and its impact on atherosclerosis. Biomed Res Int. 2015;2015:1-8.
56. Minetti M, Agati L, Malorni W. The microenvironment can shift erythrocytes from a friendly to a harmful behavior: pathogenetic implications for vascular diseases. Cardiovasc Res. 2007;75:21-28.
57. Emans ME, van der Putten K, van Rooijen KL, et al. Determinants of red cell distribution width (RDW) in cardiorenal patients: RDW is not related to erythropoietin resistance. J Card Fail. 2011;17:626-633.
58. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.
59. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352:1011-1023.
60. Doganer YC, Rohrer JE, Aydogan U, et al. Association of renal function, estimated by four equations, with coronary artery disease. Int Urol Nephrol. 2015;47:663-671.
61. Afsar B, Saglam M, Yuceturk C, et al. The relationship between red cell distribution width with erythropoietin resistance in iron replete hemodialysis patients. Eur J Intern Med. 2013;24:e25-e29.
62. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res. 1998;18:555-559.
63. Patel HH, Patel HR, Higgins JM. Modulation of red blood cell population dynamics is a fundamental homeostatic response to disease. Am J Hematol. 2015;90:422-428.
64. Uthoff H, Staub D, Socrates T, et al. PROCAM-, FRAMINGHAM-, SCORE-and SMART-risk score for predicting cardiovascular morbidity and mortality in patients with overt atherosclerosis. Vasa. 2010;39:325-333.
65. De Mulder M, Umans VA, Stam F, et al. Intensive management of hyperglycaemia in acute coronary syndromes. Study design and rationale of the BIOMArCS2 glucose trial. Diabet Med. 2011;28:1168-1175.